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Objective: To perform a retrospective external validation of miniPIERS in Zanzibar's 
referral hospital.
Methods: From February to December 2017, data were collected retrospectively on all 
cases of hypertensive disorders of pregnancy (HDP) admitted to Mnazi Mmoja Hospital, 
Zanzibar, Tanzania. The primary outcome was the predictive performance of miniPIERS 
by examining measures of discrimination, calibration, and stratification accuracy. The sec-
ondary outcome was the applicability of miniPIERS within the referral hospital setting.
Results: During this period, 2218 of 13 395 (21%) patients were identified with HDP, of 
whom 594 met the inclusion criteria. Sixty per cent of patients with adverse outcomes 
were excluded because they had experienced one of the adverse outcomes before 
admission. The discriminative ability of miniPIERS was inaccurate. It was not likely to 
aid risk stratification because of low sensitivity and low positive predictive value. The 
model showed fair discrimination in HDP before 34 weeks of gestation (area under 
the receiver operating characteristics curve 0.72, 95% confidence interval 0.63–0.82).
Conclusions: The benefit of miniPIERS appeared to be limited, although clinical condi-
tions make any validation challenging. Its application for risk stratification in preterm 
pregnancies should be further investigated.
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1  |  INTRODUC TION
Hypertensive disorders of pregnancy (HDP) are a major cause 
of maternal morbidity and mortality, complicating 2%–10%1-3 of 
pregnancies globally and accounting for 30 000–50 000 maternal 
deaths annually.1,2 This is accompanied by increased risks of peri-
natal morbidity and mortality. A majority of 90% occur in low- and 
middle-income countries, with the burden concentrated in South 
Asia and sub-Saharan Africa. Approximately 10% of maternal deaths 
in Africa can be attributed to HDP.2,4-6
Early identification of patients at increased risk of life-threaten-
ing complications of HDP would be of great value to reduce mater-
nal and perinatal mortality1,7-9; either by enabling prompt referral 
to adequate health care, or by improving the allocation of care in 
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low-resource settings. It could also help to decide between delivery 
and expectant management in preterm HDP.
In 2014, Payne et al10 developed the miniPIERS (Pre-eclampsia 
Integrated Estimate of Risk) prediction model to identify pregnant 
women in low- and middle-income countries at increased risk of hy-
pertension-related organ failure and death. Predictor variables are 
based on patient characteristics (gestational age [GA] and parity) and 
manifestations of disease (hypertension, proteinuria, visual changes, 
chest pain and/or shortness of breath, vaginal bleeding with abdom-
inal pain) on admission. MiniPIERS is a follow up to the fullPIERS 
prediction model, designed to predict adverse maternal outcomes 
of pre-eclampsia in high-income countries.11,12 MiniPIERS has been 
validated using the fullPIERS data set and performs accurately (area 
under the receiver operating characteristics curve [AUROC] 0.77, 
95% confidence interval [CI] 0.72–0.82).10 However, the applicabil-
ity in the context of a low-resource referral setting has not yet been 
confirmed, nor has its performance been validated outside the con-
text of a prospective trial.
This study aims to perform a retrospective external validation of 
miniPIERS in Zanzibar's referral hospital. In addition, it investigates 
the potential of miniPIERS in supporting decision making for allo-
cation of resources and timing of delivery in preterm pregnancies. 
Furthermore, its applicability in a low-resource referral setting and 
the share of the burden of HDP for which miniPIERS could be used 
in regular clinical conditions is assessed.
2  |  MATERIAL S AND METHODS
Zanzibar is an archipelago, semi-autonomous to the United Republic 
of Tanzania. Mnazi Mmoja Governmental Hospital (MMH), located 
in the island's only urban area, serves a population of 1.4 million as a 
referral hospital, facilitating 30% of all facility deliveries in Zanzibar. 
The majority of its patients, however, have uncomplicated pregnan-
cies.13,14 In 2017, the in-hospital maternal mortality ratio was high, at 
401/100 000 live births.13 In a retrospective study by Herklots et al,13 
pre-eclampsia and eclampsia were present in 21.4% and 7.1% of ma-
ternal deaths, respectively, with case fatality rates of 3.8% and 3.6%, 
respectively.
This study was a retrospective cohort study of case files of pa-
tients admitted to the maternity ward of MMH from February 1, 
2017 to December 31, 2017. Inclusion criteria were: single blood 
pressure measurement showing HDP after 20 weeks GA and ad-
mission before active labor. Exclusion criteria were: active labor on 
admission, occurrence of adverse outcome within 24 h of admis-
sion, unavailability of a predictor variable within 24 h of admission, 
and incomplete patient files. Project approval was obtained from 
Zanzibar's Medical Ethical Research Committee (protocol number: 
ZAMREC/0001/AUGUST/005). Informed consent was waived be-
cause the study only concerned an analysis of clinical files with ag-
gregated, anonymous outcomes.
According to the original miniPIERS study,10 HDP were defined 
as follows: (1) gestational hypertension, defined as hypertension 
(systolic >140 mm Hg or diastolic >90 mm Hg) after 20 weeks GA, 
without significant proteinuria; or (2) pre-eclampsia, defined as 
hypertension (systolic >140 mm Hg or diastolic >90 mm Hg) and 
proteinuria more than 2+ after 20 weeks GA; or (3) severe pre-ec-
lampsia, defined as either pre-eclampsia and severe hypertension 
(systolic >160 mm Hg or diastolic >110 mmHg), or pre-eclampsia and 
symptoms of organ failure (headache, blurred vision, epigastric pain, 
chest pain or shortness of breath, nausea or vomiting) after 20 weeks 
GA; or (4) chronic hypertension (systolic >140 mm Hg or diastolic 
>90 mm Hg) before 20 weeks GA without significant proteinuria. 
It was not possible to identify patients with HELLP (hemolysis, ele-
vated liver enzymes, and low platelet count) syndrome or hyperuri-
cemia, because laboratory parameters were unavailable. Active labor 
was defined as uterine contractions plus cervical dilatation of more 
than 3 cm.
Adverse maternal outcome was defined as maternal mortality 
and morbidity, including organ failure of the nervous, cardiorespi-
ratory, hematological, and renal systems.10 The miniPIERS predictor 
variables,10 systolic blood pressure, GA, parity, urine for protein, 
headache and/or visual disturbances, chest pain and/or shortness of 
breath, vaginal bleeding with abdominal pain, were collected from pa-
tient file notes for the first 24 h of admission. In the case of multiple 
measurements, the worst clinical value was used. GA was calculated 
based on, in order of preference, first-trimester ultrasound, earliest 
ultrasound, notes regarding GA, last menstrual period, or symphy-
sis fundal height (SFH). To estimate GA from SFH the following for-
mula from the Intergrowth study group was used: GA (weeks) = 6.
585838 − 2.7072585 × (SFH0.5) + 1.295291 × (SFH).16 As vaginal 
bleeding combined with abdominal pain was rarely noted, this pre-
dictor variable was adjusted to vaginal bleeding. In multiple pregnan-
cies, the lowest birthweight was extracted. As a result of the lack 
of equipment, it was not possible to assess the following outcomes: 
cortical blindness/retinal detachment, posterior reversible encepha-
lopathy, fraction of inspired oxygen, and infusion of a third parenteral 
antihypertensive. Hepatic dysfunction was redefined to a serolog-
ical bilirubin concentration of more than 100 µmol/L, because the 
International Normalized Ratio test for coagulation was unavailable.
The primary outcome was the predictive performance of miniP-
IERS by examining measures of discrimination, calibration, and strat-
ification accuracy. The secondary outcome was the applicability of 
miniPIERS within MMH, defined as the proportion of patients ad-
mitted with HDP before the onset of labor and the occurrence of an 
adverse maternal outcome.
All patients with HDP, not presenting in active labor, were included 
in this study (cohort A). Because the adverse outcome of blood trans-
fusion for antenatal severe anemia was common, and its relationship 
with HDP is unclear, a sub-analysis of cohort A was performed in 
which this outcome was not considered as an exclusion criterion nor 
as an adverse outcome (cohort B). To see if the model could aid deci-
sion-making for preterm pregnancies, a sub-analysis of cohort A was 
performed for GA below 34 weeks (cohort C). A third sub-analysis was 
performed, in which the inclusion was restricted to those patients of 
cohort A presenting with pre-eclampsia on admission only (cohort D).
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The probability of occurrence of any of the predefined adverse 
outcomes was calculated from the miniPIERS equation.10 Fisher 
exact test and Mann–Whitney U test were applied on categorical 
and continuous variables, respectively. Discrimination was defined 
as the ability of the model to differentiate between people who did 
and did not experience one of the adverse outcomes, indicated by 
the AUROC.17 The AUROC was classified using the traditional ac-
ademic point system (0.9–1.0 excellent; 0.8–0.9 good; 0.7–0.8 fair; 
0.6–0.7 poor; 0.5–0.6 fail). Calibration was defined as the agreement 
between the predicted and observed risk per decile of the cohort, 
indicated by the intercept and calibration slope of the calibration 
plot.17 Positive likelihood ratio >10 and negative likelihood ratio <0.1 
were considered to be of clinical relevance.18 Statistical analyses 
were performed using SPSS version 25 (IBM) and R. A p value below 
0.05 was considered to be of statistical significance.
3  |  RESULTS
From February 1 to December 31, 2017, 13 395 patient files were 
assessed retrospectively, out of which 2807 (21%) were identi-
fied with any hypertension measurement and 4369 (33%) did not 
have any blood pressure documented on admission. Over 70% 
(1969/2807) of patients with HDP were excluded before data col-
lection because they were admitted in active labor (Figure 1). Of the 
remaining 838 patients, 594 met the inclusion criteria (Figure 2). 
Less than half of adverse outcomes occurred in the population of 
interest, since 120/201 (60%) patients were excluded because they 
experienced one of the adverse outcomes on admission.
Compared with patients without an adverse outcome, patients 
of cohort A with an adverse outcome were significantly more likely 
to have a higher systolic blood pressure, higher proteinuria on ad-
mission, more symptoms (headache, visual disturbances, vaginal 
bleeding), to have received antihypertensive drugs, MgSO4 and cor-
ticosteroids, to deliver by cesarean section, and to have had an intra-
uterine fetal death (Table 1). Of all patients in cohort A, 81 (13.6%) 
experienced an adverse outcome and 3 (0.5%) died, of whom two 
were <34 weeks pregnant. The most prevalent adverse outcomes 
were blood transfusion (69, 11.6%), eclampsia (9, 1.5%) and acute 
renal insufficiency (6, 1.0%) (Table 2). At baseline, cohorts B and C 
were comparable to cohort A (Appendices S1–S3). Patients in co-
hort C with an adverse outcome were significantly more likely than 
patients without an adverse outcome to have higher maternal age, 
to be multiparous, to have lower GA on admission and at delivery, to 
have higher diastolic blood pressure, to have severe pre-eclampsia 
on admission, and to undergo labor induction. In cohort C, adverse 
outcome was also associated with a significantly higher number of 
low birth weight infants and neonatal deaths. Baseline results of co-
hort D (Appendix S3) showed that patients with adverse outcomes 
had significantly lower GA on admission and at delivery.
The discriminatory ability of miniPIERS was poor for cohorts A, 
B, and D (Figure 3), indicated by AUROCs of 0.64 (95% CI 0.57–0.71), 
0.680 (95% CI 0.60–0.76), and 0.62 (95% CI 0.53–0.72), respectively. 
The AUROC for cohort C was fair, at 0.72 (95% CI 0.63–0.82). The 
highest predicted probability for all cohorts was 7.4% (predetermined 
boundaries 0.7%–29.2%). When using the predicted probability to 
stratify (Table 3), the number of events decreased with increasing 
predicted probability. At the cut-off value of more than 2.0% pre-
dicted probability, sensitivity and positive predictive values were 
low for all cohorts. The specificity and negative predictive values for 
this cut-off value were relatively high, ranging from 0.78% to 0.93% 
and 0.85% to 0.92%, respectively. As a result of the small group sizes 
for the other cut-off values, the corresponding results could not be 
interpreted. The calibration curves (Figure 4; Appendix S4) showed 
a slope of 0.94 (95% CI 0.51–1.36).
4  |  DISCUSSION
Retrospective application of miniPIERS in MMH showed no discrim-
inative ability in our study population. The model showed fair dis-
crimination in the subgroup with HDP before 34 weeks GA (cohort 
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F I G U R E  2  Flow-chart miniPIERS Zanzibar part 2
Patient files  2017
n = 13,395
Excluded n = 10,588
6,219 BP normal
4,369 BP not recorded 
11 BP not recorded first 24 hours
HDP
n = 2,807
Excluded n = 1,969
1,660 HDP in labour
232 HDP after labour
77 HDP labour status unknown
HDP before active labour
n = 838
Excluded n = 244*
120 adverse outcome on admission
68 eclampsia
29 blood transfusion 
17 abruptio placentae
7 other**
124 predictor variable unavailable
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TA B L E  1  Baseline characteristics miniPIERS Zanzibar Cohort A (n = 594)a
Without adverse outcome 
(n = 513)
With adverse outcome 




Age on admission, year 28.0 ± 6.0 29.1 ± 6.0 .158 594
Age on admission <20 year 34 (6.6) 2 (2.5) .208 594
Age on admission 20–35 year 412 (80.3) 64 (79.0) .766 594
Age on admission >35 year 67 (13.1) 15 (18.5) .223 594
Parity 0 (0–2)c  1 (0–3) .186 594
Parity 0 260 (50.7) 35 (43.2) .233 594
Parity 1–4 209 (40.7) 34 (42.0) .903 594
Parity >4 44 (8.6) 12 (14.8) .098 594
Gestational age on admission (weeks) 35.9 (32.7–38.3) 36.4 (31.0–39.1) .815 594
Multiple pregnancy 11 (2.1) 3 (3.7) .421 594
Marital status married 507 (99.2) 81 (100.0) 1.000 592
Address urban district 160 (32.3) 27 (33.8) .798 576
Address rural district 130 (26.2) 19 (23.8) .682 576
Address mixed district 206 (41.5) 34 (42.5) .903 576
Clinical measures
Systolic blood pressure, mm Hg 150 (140–174) 160 (148–190) <.001 594
Diastolic blood pressure, mm Hg 97 (90–110) 100 (90–117) .058 593
Worst dipstick proteinuria (+) 0+ (0–2+) 1+ (0–2+) .005 594
Number of miniPIERS symptoms ≥1 82 (16.0) 31 (38.3) <.001 594
Headache and/or visual disturbances 78 (15.2) 25 (30.9) .001 594
Vaginal bleeding 3 (0.6) 6 (7.4) <.001 594
Chest pain and/or dyspnea 6 (1.2) 0 (0.0) 1.000 594
Severe pre-eclampsia 129 (25.2) 28 (34.6) .079 593
Mild pre-eclampsia 34 (6.6) 4 (4.9) .807 593
Other HDP 349 (68.2) 49 (60.5) .203 593
Antihypertensive drugs (oral or intravenous) 242 (47.2) 57 (70.4) <.001 594
Prophylactic MgSO4 147 (28.8) 44 (54.3) <.001 592
Corticosteroids 83 (16.2) 21 (25.9) .040 594
Labor induction 180 (35.4) 36 (44.4) .136 590
Pregnancy outcomes
Admission to delivery interval, day 2.2 ± 6.0 2.4 ± 2.9 <.001 591
GA at delivery, week 36.1 (32.9–38.7) 36.7 (31.6–39.5) .985 591
Delivery at GA <34 week 166 (32.5) 27 (33.8) .898 591
Mode of delivery, spontaneous vaginal 347 (68.0) 31 (38.3) <.001 591
Mode of delivery, instrumental vaginal 2 (0.4) 1 (1.2) .358 591
Mode of delivery, cesarean section 161 (31.6) 49 (60.5) <.001 591
Intrauterine fetal death (GA ≥ 20 week and/or birth 
weight ≥500 g)
37 (7.4) 13 (16.5) .015 582
Neonatal death 8 (1.8) 3 (5.0) .135 500
Birthweight, kg 2.9 (2.5–3.3) 2.9 (2.0–3.5) .742 569
Abbreviations: GA, gestational age; HDP, hypertensive disorders of pregnancy.
aValues are given as mean ± SD, median (interquartile range), or number (percentage). 
bp values calculated using χ2 test for categorical variables and Mann–Whitney U test for continuous variables. 
cInterquartile range defined according to Tukey's hinge. 
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C, AUROC 0.72, 95% CI 0.63–0.82). The model was not likely to aid 
risk stratification because of low sensitivity, positive predictive value, 
and positive likelihood ratio. The benefits of miniPIERS in this setting 
were limited, with most patients admitted in active labor and over 
half of the adverse maternal outcomes occurring before eligibility.
The burden of HDP in MMH was high at 21%, compared with a 
global rate of 10%.2,3 As far as can be reconstructed from a retrospec-
tive approach, care provided to this patient group was substandard, 
reflecting an overstretched health system. This included poor docu-
mentation and a large amount of missing data with, for example, no 
documentation of blood pressure measurement in 32.5% of the cases 
(4358/13 395). This compares with a retrospective study of Maaløe at 
al.15 from October 2014 till January 2016 in MMH, which showed that 
blood pressure was not recorded in 22%–24% of patient files.
Our population was comparable to the original miniPIERS study 
in terms of maternal age, parity, GA, and blood pressure at admission. 
We found an adverse outcome rate of 13.6%, which is lower than 
that found in the original study (19.3% vs 12.5% within 48 h) despite 
the fact that the mortality ratio was higher in our cohort (3/594 vs 
2/2081).10 This could be the result of a number of adverse outcomes 
TA B L E  2  Adverse outcomes miniPIERS Zanzibara
Cohort A (n = 594) Cohort B (n = 611) Cohort C (n = 219) Cohort D (n = 195)
Any adverse outcome 81 (13.6) 54 (8.8) 31 (14.2) 32 (16.4)
Central nervous system
Eclampsia (≥1 fit) 9 (1.5) 9 (1.5) 4 (1.8) 3 (1.5)
Glasgow coma score <13 2 (0.3) 2 (0.3) 1 (0.5) 1 (0.5)
Stroke or reversible ischemic neurological 
deficit
1 (0.2) 1 (0.2) 0 (0.0) 0 (0.0)
Cardiorespiratory
Continuous use of vasoactive drugs 1 (0.2) 1 (0.2) 0 (0.0) 0 (0.0)
Myocardial ischemia or infarction 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Oxygen saturation <90% 2 (0.3) 2 (0.3) 2 (0.9) 1 (0.5)
Respiratory rate >40 or <6/min 1 (0.2) 1 (0.2) 1 (0.5) 0 (0.0)
Intubation (other than for cesarean section) 3 (0.5) 3 (0.5) 1 (0.5) 1 (0.5)
Pulmonary edema 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Hematological
Transfusion of any blood productb  69 (11.6) 86 (14.1) 24 (11.0) 26 (13.3)
Main reason for transfusion severe anemia 30 (5.1) 47 (7.7) 7 (3.2) 11 (5.6)
Main reason for transfusion antepartum 
hemorrhage
2 (0.3) 2 (0.3) 2 (0.9) 2 (1.0)
Main reason for transfusion postpartum 
hemorrhage
19 (3.2) 21 (3.4) 6 (2.7) 6 (3.1)
Main reason for transfusion unknown 18 (3.0) 18 (2.9) 9 (4.1) 7 (3.6)
Platelets <50 × 109/L with no transfusion 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Hepatic
Hepatic dysfunction (bilirubin >100 µmol/L) 3 (0.5) 3 (0.5) 2 (0.9) 1 (0.5)
Hepatic hematoma or rupture 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Renal
Acute renal insufficiency (creatinine 
>150 µmol/L)
6 (1.0) 7 (1.1) 5 (2.3) 4 (2.1)
Dialysis 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Other
Placental abruption 4 (0.7) 4 (0.7) 2 (0.9) 1 (0.5)
Severe ascites (≥0.5 L) 2 (0.3) 2 (0.3) 1 (0.5) 2 (1.0)
Uterine rupture 1 (0.2) 1 (0.2) 1 (0.5) 1 (0.5)
Postpartum psychosis 2 (0.3) 2 (0.3) 1 (0.5) 2 (1.0)
Maternal death 3 (0.5) 3 (0.5) 2 (0.9) 1 (0.5)
aValues are given as number (percentage). 
bThe sum of patients who experienced a transfusion of any blood product in cohort B is lower than the subdivisions because two patients were 
transfused for both severe anemia and postpartum hemorrhage. 
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not being included in the analysis. However, this effect is likely to 
be negligible considering the severity of the outcomes considered. It 
could also be indicative of delayed patient presentation in our popu-
lation. The original miniPIERS study does not provide any information 
on the number of patients presenting with adverse outcome on ad-
mission. We found that almost 60% of adverse outcomes are already 
present on admission. Differences in referral patterns are therefore 
likely to have a major influence on the overall adverse outcome rate. 
Similarly to the original miniPIERS study, we found that the most fre-
quent adverse outcome was blood transfusion (11.6% vs 8.4%).19
The main interest of the present study is that it is the first external 
validation attempt in a setting for which miniPIERS has been developed. 
We faced a dilemma when designing the study given the challenges of 
the clinical setting. A prospective approach, although enabling accurate 
and complete data collection, relies on resources that are most often 
external and not sustainable in real clinical practice. They are likely to 
overestimate the range of applicability of the model under real clinical 
conditions. As an illustration, the number of files with any blood pressure 
measurement increased from 60% to more than 85% when external re-
search assistants present around the clock were involved in the context 
of another study in the last 3 months of data collection (Figure 1).
We eventually chose a retrospective approach because, as the 
original article on the miniPIERS did not provide any information 
on the applicability of the model, we would contribute more to the 
subject by giving priority to assessing this aspect. We also acknowl-
edged that the evaluation of the predictive performance of the 
model might be less accurate and conclusions about performance 
needed to be drawn with caution. We chose for instance to adapt 
the inclusion criteria by using only one blood pressure reading and 
not two with a 4-h interval because clinical decision making is based 
on that blood pressure measurement in practice. The amount of 
missing data of predictor variables, leading to selection bias, is an-
other limitation of this approach. For example, GA was solely avail-
able by SFH in 224/594 (37%) cases.
By contrast with the original study, we provide an overview of 
all patients presenting in MMH with HDP. We found that more than 
half of adverse outcomes were already present at admission, and the 
majority of patients with HDP presented in labor. Combining poor 
clinical monitoring and severe conditions at admission means that 
only a minority of patients with HDP will benefit from miniPIERS.
We do not recommend using miniPIERS for risk stratification in 
MMH under the current conditions, although its performance could be 
better in conditions that more closely resemble the conditions in which 
it was first applied. Future studies are required in a multicenter setting 
with a higher level of care, but should ideally be conducted as closely as 
F I G U R E  3  Receiver operating characteristics curves miniPIERS 
Zanzibar




n/n Sens. Spec. PPV NPV LR positiveb 
LR 
negativeb 
0.0%–2.0% A 66/541 – – – – 0.88 2.50
B 42/556 – – – – 0.84 2.88
C 22/186 – – – – 0.81 2.27
D 22/149 – – – – 0.88 1.41
2.1%–5.0% A 15/50 0.19 0.93 0.28 0.88 2.71 0.87
B 12/52 0.22 0.92 0.22 0.92 3.09 0.84
C 9/31 0.29 0.87 0.27 0.88 2.48 0.80
D 10/44 0.31 0.78 0.22 0.85 1.50 0.87
5.1%–8.0% A 0/3 0.00 1.00 0.00 0.86 – –
B 0/3 0.00 0.99 0.00 0.91 0.00 –
C 0/2 0.00 0.99 0.00 0.86 0.00 –
D 0/2 0.00 0.99 0.00 0.83 0.00 –
Abbreviations: NPV, negative predictive value; PPV, positive predictive value; Sens., sensitivity; Spec., specificity.
aUpper limit of predicted probability range used to define a positive test for sensitivity, specificity, positive predictive value and negative predictive value. 
bLikelihood ratio for each category calculated using the method described by Deeks et al.18 
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possible to realistic clinical conditions. The proportion of the popula-
tion studied for which miniPIERS can be applied in primary, secondary, 
and tertiary care should also be included to evaluate the contribution 
of miniPIERS to a sustainable referral system. Finally, the fair predictive 
performance in preterm pregnancy justifies further investigation.
In conclusion, we assessed the performance of miniPIERS to predict 
increased risk of adverse outcomes related to HDP in patients admitted 
to MMH. The benefit of miniPIERS appeared to be limited, although 
clinical conditions make any validation challenging. Its application for 
risk stratification in preterm pregnancies should be further investigated.
CONFLIC T OF INTERE S T
The lead author affirms that this manuscript is an honest, accurate, 
and transparent account of the study being reported; that no im-
portant aspects of the study have been omitted; and that any dis-
crepancies from the study as planned have been explained. We 
have followed EQUATOR reporting guidelines of the TRIPOD pro-
tocol (Transparent Reporting of a multivariable prediction model for 
Individual Prognosis Or Diagnosis).
AUTHOR CONTRIBUTIONS
BJ, TH, and EM participated in the design of the study. EM and SY 
performed the data management. EM performed all analyses. All au-
thors (EM, TH, SY, TM, AF, BP, and BJ) contributed to the interpreta-
tion of the results. BJ and EM drafted the manuscript; BP, AF, TH, 
and TM contributed by revising it for important intellectual content. 
All authors have approved the final version of the manuscript.
R E FE R E N C E S
 1. Ukah UV, De Silva DA, Payne B, et al. Prediction of adverse ma-
ternal outcomes from pre-eclampsia and other hypertensive dis-
orders of pregnancy: a systematic review. Pregnancy Hypertens. 
2018;11:115-123.
 2. Duley L. The global impact of pre-eclampsia and eclampsia. Semin 
Perinatol. 2009;33(3):130-137.
 3. Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclamp-
sia and the other hypertensive disorders of pregnancy. Best Pract 
Res Clin Obstet Gynaecol. 2011;25(4):391-403.
 4. Kassebaum NJ, Bertozzi-Villa A, Coggeshall MS, et al. Global, re-
gional, and national levels and causes of maternal mortality during 
1990–2013: a systematic analysis for the Global Burden of Disease 
Study 2013. Lancet. 2014;384:980-1004.
 5. Nakimuli A, Nakubulwa S, Kakaire O, et al. The burden of mater-
nal morbidity and mortality attributable to hypertensive disor-
ders in pregnancy: a prospective cohort study from Uganda. BMC 
Pregnancy Childbirth. 2016;4(16):205.
 6. Browne JL, van Nievelt SW, Srofenyoh EK, et al. Criteria-based audit 
of quality of care to women with severe pre-eclampsia and eclampsia 
in a referral hospital in Accra, Ghana. PLoS One. 2015;10(4):e0125749.
 7. Thangaratinam S, Allotey J, Marlin N, et al. Development and val-
idation of Prediction models for Risks of complications in Early-
onset Pre-eclampsia (PREP): a prospective cohort study. Health 
Technol Assess. 2017;21(18):1-100.
 8. von Dadelszen P, Firoz T, Donnay F, et al. Preeclampsia in low and 
middle income countries-health services lessons learned from the 
PRE-EMPT (PRE-Eclampsia-Eclampsia Monitoring, Prevention and 
Treatment) project. J Obstet Gynaecol Can. 2012;34(10):917-926.
 9. von Dadelszen P, Magee LA. Pre-eclampsia: an update. Curr 
Hypertens Rep. 2014;16(8):454.
 10. Payne BA, Hutcheon JA, Ansermino JM, et al. A risk prediction 
model for the assessment and triage of women with hypertensive 
disorders of pregnancy in low-resourced settings: the miniPIERS 
(Pre-eclampsia Integrated Estimate of RiSk) multi-country prospec-
tive cohort study. PLoS Medicine. 2014;11(1):e1001589.
 11. von Dadelszen P, Payne B, Li J, et al. Prediction of adverse maternal 
outcomes in pre-eclampsia: development and validation of the full-
PIERS model. Lancet. 2011;377(9761):219-227.
 12. Ukah UV, Payne B, Lee T, et al. External validation of the fullPIERS 
model for predicting adverse maternal outcomes in pregnancy 
hypertension in low- and middle-income countries. Hypertension. 
2017;69(4):705-711.
 13. Herklots T, Van Acht L, Meguid T, et al. Severe maternal morbidity 
in Zanzibar’s referral hospital: measuring the impact of in-hospital 
care. PLoS One. 2017;12(8):e0181470.
 14. Maaløe N, Housseine N, van Roosmalen J, et al. Labour manage-
ment guidelines for a Tanzanian referral hospital: the participa-
tory development process and birth attendants’ perceptions. BMC 
Pregnancy Childbirth. 2017;17(1):175.
 15. Maaløe N, Andersen CB, Housseine N, et al.Intrapartum manage-
ment of severe hypertensive disorders and effect of locally-tailored 
clinical guidelines: pre-post study from Zanzibar’s referral hospital. 
Unpublished article, March 2018. Available upon request to nan-
nam@sund.ku.dk.
 16. Papageorghiou AT, Ohuma EO, Gravett MG, et al. International stan-
dards for symphysis-fundal height based on serial measurements 
from the Fetal Growth Longitudinal Study of the INTERGROWTH-
21st Project: prospective cohort study in eight countries. BMJ. 
2016;355:i5662.
 17. Moons KGM, Altman DG, Reitsma JB, et al. Transparent Reporting 
of a multivariable prediction model for Individual Prognosis Or 
Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 
2015;162:W1-W73.
 18. Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ. 
2004;329(7458):168-169.
 19. Housseine N, Browne JL, Rijken MJ.Perinatal morbidity, neona-
tal and intra-uterine foetal death in Zanzibar’s referral hospital. 
October 2017–June 218. Available on request to natasha.hous-
seine@outlook.com.
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section.
How to cite this article: Meij E, Herklots T, Yussuf S, et al. 
Retrospective validation study of miniPIERS prediction model 
in Zanzibar. Int J Gynecol Obstet. 2020;00:1–7. https://doi.
org/10.1002/ijgo.13493
F I G U R E  4  Calibration plot Zanzibar cohort A
